Lung cancer is a major cause of morbidity and mortality and the majority of new cases are advanced non–small-cell lung cancer (NSCLC).
Gefitinib belongs to a new class of anti cancer drugs called tyrosine-kinase inhibitors which preferentially targets cancer cells unlike the older cancer chemotherapeutic drugs.
Exemestane is the latest in the family of aromatase inhibitors which provide the convenience of long-term oral therapy in a large sub-group of breast cancer patients.
Temozolomide is probably the most important discovery in the new millennium. This drug brought hope to thousands of brain tumour patients across the world.
Capecitabine is a prodrug which metabolizes in higher concentrations in tumour cells to the active drug 5-Fluorouracil (5-FU).
Don't miss our special offers. Get the theme today!